Risk Factors for Treatment Failure and Recurrence after Metronidazole Treatment for Clostridium difficile-associated Diarrhea
2
조회
0
다운로드
5
인용
0
참고문헌
초록
Background/Aims: The incidence of treatment failure or recurrence of Clostridium difficile-associated diarrhea (CDAD) following metronidazole treatment has increased recently. We studied the treatment failure, recurrence rate, and risk factors predictive of treatment failure and recurrence after metronidazole treatment for CDAD. Methods: We retrospectively identified consecutive patients who were admitted and treated for CDAD at a single tertiary institution in Korea over a recent 10-year period (i.e., 1998-2008). Results:Metronidazole was administered as the initial treatment to 111 of 117 patients (94.9%) with CDAD. Fourteen patients (12.6%) had no clinical response to the metronidazole treatment, and in 13 patients (13.4%) CDAD recurred after successful metronidazole treatment. Diabetes mellitus (p=0.014) and sepsis (p=0.002) were independent risk factors for metronidazole treatment failure. Patients who had received surgery within 1 month before CDAD developed were more likely to experience a recurrence after metronidazole treatment (p=0.032). Vancomycin exhibited a higher response rate after treatment failure, and metronidazole showed a reasonable response rate in the treatment of recurrence. Treatment failure and recurrence rates increased with time after metronidazole treatment for CDAD over the 10-year study period. Conclusions: Our data suggest that diabetes mellitus and sepsis are independent risk factors for metronidazole treatment failure, and that operation history within 1 month of development of CDAD is a predictor of a recurrence after metronidazole treatment.
Abstract
Background/Aims: The incidence of treatment failure or recurrence of Clostridium difficile-associated diarrhea (CDAD) following metronidazole treatment has increased recently. We studied the treatment failure, recurrence rate, and risk factors predictive of treatment failure and recurrence after metronidazole treatment for CDAD. Methods: We retrospectively identified consecutive patients who were admitted and treated for CDAD at a single tertiary institution in Korea over a recent 10-year period (i.e., 1998-2008). Results:Metronidazole was administered as the initial treatment to 111 of 117 patients (94.9%) with CDAD. Fourteen patients (12.6%) had no clinical response to the metronidazole treatment, and in 13 patients (13.4%) CDAD recurred after successful metronidazole treatment. Diabetes mellitus (p=0.014) and sepsis (p=0.002) were independent risk factors for metronidazole treatment failure. Patients who had received surgery within 1 month before CDAD developed were more likely to experience a recurrence after metronidazole treatment (p=0.032). Vancomycin exhibited a higher response rate after treatment failure, and metronidazole showed a reasonable response rate in the treatment of recurrence. Treatment failure and recurrence rates increased with time after metronidazole treatment for CDAD over the 10-year study period. Conclusions: Our data suggest that diabetes mellitus and sepsis are independent risk factors for metronidazole treatment failure, and that operation history within 1 month of development of CDAD is a predictor of a recurrence after metronidazole treatment.
참고문헌 (18)
- Barbut F, "Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study", Arch Intern Med, 156, pp.1449~1454 (1996)
- Bartlett JG, "Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism", Clin Infect Dis, 18(Suppl 4), pp.S265~S272 (1994)
- Musher DM, "Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole", Clin Infect Dis, 40, pp.1586~1590 (2005)
- Nair S, "Clostridium difficile colitis: factors influencing treatment failure and relapse--a prospective evaluation", Am J Gastroenterol, 93, pp.1873~1876 (1998)
- Kuijper EJ, "Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?", Clin Infect Dis, 47, pp.63~65 (2008)
- Zar FA, "A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity", Clin Infect Dis, 45, pp.302~307 (2007)
- Fernandez A, "Factors associated with failure of metronidazole in Clostridium difficile-associated disease", J Clin Gastroenterol, 38, pp.414~418 (2004)
- McFarland LV, "Epidemiology, risk factors and treatments for antibiotic-associated diarrhea", Dig Dis, 16, pp.292~307 (1998)
- Teasley DG, "Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis", Lancet, 2, pp.1043~1046 (1983)
- Pepin J, "Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada", Clin Infect Dis, 40, pp.1591~1597 (2005)
- 변태준, "Clostridium difficile-Associated Disease (CDAD)의 최근 임상양상의 변화", 대한소화기학회지, 54(1), pp.13~19 (2009), 대한소화기학회
- Joshi N, "Infections in patients with diabetes mellitus", N Engl J Med, 341, pp.1906~1912 (1999)
- Bartlett JG, "Clinical practice. Antibiotic-associated diarrhea", N Engl J Med, 346, pp.334~339 (2002)
- Al-Nassir WN, "Comparison of clinical and microbiological response to treatment of Clostridium difficileassociated disease with metronidazole and vancomycin", Clin Infect Dis, 47, pp.56~62 (2009)
- Barbut F, "Epidemiology of Clostridium difficile-associated infections", Clin Microbiol Infect, 7, pp.405~410 (2001)
- Edlund C, "Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy", Clin Infect Dis, 25, pp.729~732 (1997)
- McFarland LV, "Breaking the cycle:treatment strategies for 163 cases of recurrent Clostridium difficile disease", Am J Gastroenterol, 97, pp.1769~1775 (2002)
- Pépin J, "Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada", Clin Infect Dis, 42, pp.758~764 (2006)